We develop novel, engineered protein subunit vaccines. Using our platform technology for protein stabilization, we have been able to engineer stabilizing mutations in protein antigens to enhance elicitation of neutralizing antibody responses in vaccine formulations. Our influenza vaccine candidates include microbially expressed stem regions of the influenza hemagglutinin (HA) protein, which in combination with recombinant HA, elicit improved breadth of protection compared to existing influenza vaccines. Separately, we have developed thermo-tolerant, efficacious vaccines for protection against SARS-CoV-2 and its evolving variants.
Mynvax has developed multiple collaborations in India and overseas, with leading researchers in vaccine design, formulation expertise and clinical development. As a biotech start-up incubated at the Indian Institute of Science, we have deep collaboration with laboratories at IISc. In addition, Mynvax has also built commercial relationships with CDMOs and large vaccine manufacturers. Some of Mynvax’s programs are grant funded by leading Indian Government funding agencies.